Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations
2019年6月13日 更新者:GlaxoSmithKline
A Phase IV, Open-Label, Multi-Center Study to Evaluate the Safety and the 1-year Persistence of Antibody Response Among Children Who Received 4 Doses of the GSK MenACWY Conjugate Vaccine at 2, 4, 6 and 12 Months of Age in South Korea
This is Phase IV, Open label, Multicenter study.
Subject's parents and/or legal guardian will be provided information about the trial.
If interested and if eligible, they will then be asked to provide signed informed consent.
The initial study visit can occur immediately after signed informed consent has been obtained.
Approximately 135 subjects will be enrolled to receive 4 doses of intramuscular MenACWY vaccine at 2, 4, 6 and 12 months of age.
研究概览
研究类型
介入性
注册 (实际的)
128
阶段
- 第四阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Ansan si、大韩民国、425 707
- GSK Investigational Site
-
Incheon、大韩民国、400 711
- GSK Investigational Site
-
Jeonju、大韩民国、561 712
- GSK Investigational Site
-
Seongnam si、大韩民国、463 707
- GSK Investigational Site
-
Seoul、大韩民国、110 744
- GSK Investigational Site
-
Seoul、大韩民国、158 710
- GSK Investigational Site
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
2个月 至 2年 (孩子)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Healthy male and female 2 month-old infants (55 - 89 days) on the day of consent.
- Infants whose parents or legal guardians have voluntary given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.
- Infants whose parents or legal guardians can comply with study procedures including follow-up
Exclusion Criteria:
- Previously received any meningococcal A, C, W and Y vaccines.
- Previous confirmed or suspected disease caused by N. meningitidis or who have had household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection at any time since birth.
- Progressive, unstable or uncontrolled clinical conditions.
- A history of anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component, such as latex allergy.
- Experienced significant acute or chronic infection within the previous 7 days or have experienced fever (temperature ≥ 38.0°C [100.4°F]) within the previous 3 days.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- Received treatment with systemic administration corticosteroids (PO/IV/IM) for more than 14 consecutive days from birth
- Ever received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation (including Hepatitis B immune globulin) at any time since birth and for the full length of the study.
- Any bleeding disorder which is considered as a contraindication to intramuscular injection or blood draw.
- Any condition which, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study.
- Received or are planning to receive any investigational or non-registered medicinal product from birth and throughout the study.
- Received oral or parenteral antibiotic treatment in the 3 days prior to the scheduled blood draw (topical antibiotics are acceptable, including antibiotic eye drops).
- Relatives of site research staff working on this study.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:MenACWY Group
Healthy male and female infants approximately 2 months (55-89 days) of age on the day of consent, who will receive 4 doses of the GSK MenACWY Conjugate Vaccine, administered intramuscularly at 2,4,6 ad 12 months of age.
|
Four Intramuscular doses of MenACWY vaccine at 2, 4, 6 and 12 months of age followed by two blood samples at 13 and 24 months of age.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Subjects With Any Solicited Adverse Events (AEs) Within 30 Minutes After Each Vaccination.
大体时间:Within 30 minutes of each vaccination
|
Solicited signs and symptoms occurring within 30 minutes following each vaccination, include solicited local events (e.g.
injection site erythema, induration and tenderness -threshold for Erythema and Induration: Type II- None [<10mm], Any[>=10 mm]), solicited systemic events (e.g.
change in eating habits, sleepiness, irritability, vomiting, diarrhea, fever[ body temperature >=38°C measured preferably via tympanic route]), and any other solicited event like use of analgesic/antipyretics for treatment or for prophylaxis
|
Within 30 minutes of each vaccination
|
|
Number of Subjects With Any Solicited Local AEs From Day 1 to Day 7 After Each Vaccination
大体时间:From Day 1 to Day 7 after each vaccination
|
Solicited local AEs reported from day 1 to day 7 after each vaccination were assessed.
Assessed local symptoms include injection site erythema, injection site induration and injection site tenderness.
Any = incidence of a particular symptom regardless of intensity grade.Threshold for Erythema and Induration: Type II None (<10 mm), Any (>=10 mm)
|
From Day 1 to Day 7 after each vaccination
|
|
Number of Subjects With Any Solicited Systemic AEs From Day 1 to Day 7 After Each Vaccination.
大体时间:From Day 1 to Day 7 after each vaccination
|
Solicited systemic AEs reported from day 1 to day 7 after each vaccination were assessed.
Assessed systemic symptoms include change in eating habits, sleepiness, irritability, vomiting, diarrhea and fever (body temperature ≥ 38°C (100.4°F)).
|
From Day 1 to Day 7 after each vaccination
|
|
Number of Subjects With Any Medically Attended Unsolicited AEs and AEs Leading to Premature Withdrawal
大体时间:From Day 1 to Visit 6 (at 24 Months of age)
|
An unsolicited adverse event is an adverse event that was not solicited using a Subject Diary and that was spontaneously communicated by a subject parent(s)/legal guardian(s)] who has signed the informed consent.
All medically attended unsolicited AEs were collected from Day 1 to Visit 6.
|
From Day 1 to Visit 6 (at 24 Months of age)
|
|
Number of Subjects With Serious AEs (SAEs)
大体时间:From Day 1 to Visit 6 (At 24 months of age)
|
Subjects reporting SAEs from day 1 to visit 6 (at 24 months of age) were assessed.
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in one or more of the following: death, is life-threatening, required or prolonged hospitalization, persistent or significant disability/incapacity, congenital anomaly/or birth defect, An important and significant medical event that may not be immediately life threatening or resulting in death or hospitalization but, based upon appropriate medical judgment, may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above.
|
From Day 1 to Visit 6 (At 24 months of age)
|
|
Percentage of Subjects With Human Serum Bactericidal Assay (hSBA) Titers ≥ 8 Against Each N.Meningitidis Serogroup A,C,W and Y at 24 Months of Age.
大体时间:At 24 months of age (Visit 6)
|
To assess antibody persistence against N. meningitidis serogroups A, C, W and Y at 1 year after completion of a 4-dose infant vaccination series (2, 4, 6 and 12 months of age) of MenACWY vaccine as measured by serum bactericidal assay using human serum complement.
|
At 24 months of age (Visit 6)
|
|
Percentage of Subjects With Rabbit Serum Bactericidal Assay (rSBA) Titers ≥ 8, Against Each N.Meningitidis Serogroup at 24 Months of Age
大体时间:At 24 months of age (Visit 6)
|
To assess antibody persistence against N. Meningitidis serogroups A, C, W and Y at 1 year after completion of a 4-dose infant vaccination series (2, 4, 6 and 12 months of age) of MenACWY vaccine as measured by serum bactericidal assay using rabbit serum complement
|
At 24 months of age (Visit 6)
|
|
Percentage of Subjects With Rabbit Serum Bactericidal Assay (rSBA) Titers ≥ 128 Against Each N.Meningitidis Serogroup at 24 Months of Age
大体时间:At 24 months of age (Visit 6)
|
To assess antibody persistence against N. Meningitidis serogroups A, C, W and Y at 1 year after completion of a 4-dose infant vaccination series (2, 4, 6 and 12 months of age) of MenACWY vaccine as measured by serum bactericidal assay using rabbit serum complement
|
At 24 months of age (Visit 6)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Subjects With hSBA ≥8 Against Each N. Meningitidis Serogroups A, C, W and Y at 13 Months of Age
大体时间:At 13 months of age (Visit 5)
|
To assess antibody response against N. meningitidis serogroups A, C, W and Y at 1 month after completion of a 4-dose infant vaccination series (2, 4, 6 and 12 months of age) of MenACWY vaccine as measured by serum bactericidal assay using human serum complement.
|
At 13 months of age (Visit 5)
|
|
Percentage of Subjects With rSBA Titers ≥ 8 Against Each N. Meningitidis Serogroups A, C, W and Y at 13 Months of Age
大体时间:At 13 months of age (Visit 5)
|
To assess antibody response against N. meningitidis serogroups A, C, W and Y at 1 month after completion of a 4-dose infant vaccination series (2, 4, 6 and 12 months of age) of MenACWY vaccine as measured by serum bactericidal assay using rabbit serum complement.
|
At 13 months of age (Visit 5)
|
|
Percentage of Subjects With rSBA Titers ≥ 128 Against Each N. Meningitidis Serogroups A, C, W and Y at 13 Months of Age
大体时间:At 13 months of age (Visit 5)
|
To assess antibody response against N. meningitidis serogroups A, C, W and Y at 1 month after completion of a 4-dose infant vaccination series (2, 4, 6 and 12 months of age) of MenACWY vaccine as measured by serum bactericidal assay using rabbit serum complement.
|
At 13 months of age (Visit 5)
|
|
hSBA Geometric Mean Titers (GMTs) Against Each N. Meningitidis Serogroups A, C, W and Y at 24 Months of Age
大体时间:At 24 months of age (Visit 6)
|
To assess persistence of antibody response in terms of GMTs using hSBA assay against N. meningitidis serogroups A, C, W and Y at 1 year after completion of a 4-dose infant vaccination series (2, 4, 6 and 12 months of age) of MenACWY vaccine.
|
At 24 months of age (Visit 6)
|
|
rSBA GMTs Against Each N. Meningitidis Serogroups A, C, W and Y at 24 Months of Age
大体时间:At 24 months of age (Visit 6)
|
To assess persistence of antibody response in terms of GMTs using rSBA assay against N. meningitidis serogroups A, C, W and Y at 1 year after completion of a 4-dose infant vaccination series (2, 4, 6 and 12 months of age) of MenACWY vaccine.
|
At 24 months of age (Visit 6)
|
|
hSBA GMTs Against Each N. Meningitidis Serogroups A, C, W and Y at 13 Months of Age
大体时间:At 13 months of age (Visit 5)
|
To assess antibody response in terms of GMTs using hSBA assay against N. meningitidis serogroups A, C, W and Y at 1 month after completion of a 4-dose infant vaccination series (2, 4, 6 and 12 months of age) of MenACWY vaccine.
|
At 13 months of age (Visit 5)
|
|
rSBA GMTs Against Each N. Meningitidis Serogroups A, C, W and Y at 13 Months of Age.
大体时间:At 13 months of age (Visit 5)
|
To assess antibody response in terms of GMTs using rSBA assay against N. meningitidis serogroups A, C, W and Y at 1 month after completion of a 4-dose infant vaccination series (2, 4, 6 and 12 months of age) of MenACWY vaccine.
|
At 13 months of age (Visit 5)
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2015年7月13日
初级完成 (实际的)
2017年12月28日
研究完成 (实际的)
2017年12月28日
研究注册日期
首次提交
2015年5月13日
首先提交符合 QC 标准的
2015年5月15日
首次发布 (估计)
2015年5月18日
研究记录更新
最后更新发布 (实际的)
2019年6月27日
上次提交的符合 QC 标准的更新
2019年6月13日
最后验证
2019年6月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.